Therefore, for patients with CD99-overexpressing gliomas, it is essential to consider tumor adaptiveness during treatment to prevent drug resistance, and closer clinical monitoring should be conducted to improve the effectiveness of treatment [112]. The gene discussed is CD99; the disease is neoplasm.